Business Context and Reporting Period
Company: Teva Pharmaceutical Industries Ltd.
Filing Type: Form 8-K (Current Report)
Report Date: July 31, 2024
Reporting Period: Second Quarter ended June 30, 2024
This filing serves as a notification that Teva issued a press release on July 31, 2024, announcing its financial results for the second quarter of 2024. The detailed results are incorporated by reference via Exhibit 99.1.
Key Financial Metrics
The provided text is a cover document for the Form 8-K and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of the Q2 2024 results announcement.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. It explicitly states that the information in Item 2.02 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 ("Teva Reports 2024 Second Quarter Financial Results") for actual revenue, earnings, and cash flow figures.
- Verify the specific details of the Q2 2024 performance and any year-over-year comparisons in the full press release.
- Check for updated guidance or strategic updates mentioned in the referenced press release.
- Confirm the status of any legal or regulatory contingencies discussed in the full report.